E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 positive living donor. |
|
E.1.1.1 | Medical condition in easily understood language |
Prevention of kidney graft rejection in patients who have received a kidney transplant due to chronic renal insufficiency. |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Immune system processes [G12] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10050436 |
E.1.2 | Term | Prophylaxis against renal transplant rejection |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the short-term safety and tolerability of TX200-TR101 from the day of TX200-TR101 infusion within 28 days post TX200-TR101 infusion. |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the effect of TX200-TR101 on acute graft-related outcomes from the day of TX200-TR101 infusion through to Week 84 in terms of biopsy-confirmed acute rejection (BCAR). • To evaluate the effect of TX200-TR101 on long-term safety outcomes from the day of TX200-TR101 infusion through to Week 84 in terms of treatment emergent adverse events(TEAEs). • To evaluate the reduction of immunosuppression over time through to Week 84. • To evaluate TX200-TR101 localisation in the graft at Week 16. • To evaluate the effect of TX200-TR101 on chronic graft-related outcomes from the day of TX200-TR101 infusion through to Week 84.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion Criteria (All Transplant Recipients) 1. Willing and able to provide written informed consent (IC) in accordance with local regulations and governing Independent Ethics Committee (IEC)/Institutional Review Board (IRB) requirements prior to any procedure or evaluation performed specifically for the sole purpose of the study. 2. Male or female aged between 18 and 70 (inclusive) years. 3. Have diagnosis of ESRD and currently waiting for a new kidney from an identified live donor. 4. Subjects who will be single organ recipients (kidney). 5. Normal or non-clinically significant abnormality in the electrocardiogram (ECG), at investigator’s discretion. 6. Women who are of childbearing potential must have a negative serum pregnancy test at screening and before transplantation. 7. Able and willing to use a highly effective method of contraception (see Appendix 2) from the signing of the informed consent through the last study visit, for male and female subjects with reproductive potential.
Additional Inclusion Criteria (Transplant Recipients to be Administered TX200 TR101 Only) The following additional criteria must be met for transplant recipients to be administered TX200 TR101: 1. HLA-A*02 negative typing (the kidney graft needs to be HLA A*02 positive). 2. HLA-A*69 negative typing. 3. Adequate venous access for leukapheresis, and no other contraindications for leukapheresis.
Inclusion Criteria (All Transplant Donors) 1. Willing and able to provide written IC in accordance with local regulations and governing IEC/IRB requirements prior to any procedure or evaluation performed specifically for the sole purpose of the study. 2. Aged at least 18 years on the day of signing the IC form. 3. ABO blood type compatible with the organ recipient. 4. Negative serology for HIV and syphilis. 5. Willing to provide personal and medical/biological data and samples for the study analysis.
Additional Inclusion Criterion (Transplant Donors for Transplant Recipients to be Administered TX200-TR101 Only) The following additional inclusion criterion must be met for transplant donors for transplant recipients to be administered TX200 TR101: 1. HLA-A*02 positive typing. |
|
E.4 | Principal exclusion criteria |
Exclusion Criteria (All Transplant Recipients) 1. HLA identical to the prospective organ donor. 2. Subjects with prior organ transplant. 3. Known hypersensitivity to study medication ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalisation. 4. Known hypersensitivity or contraindications for anti-thymocyte globulin (ATG), tacrolimus or mycophenolic acid (MPA)/ mycophenolate mofetil (MMF). 5. Positive serology for human immunodeficiency virus (HIV) or syphilis. 6. Evidence of active or occult hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection. 7. Subjects who are Epstein-Barr Virus (EBV) seronegative. 8. Positive flow cytometric crossmatch using donor lymphocytes and recipient serum. 9. Subjects with panel-reactive antibody (PRA) >20% within 6 months prior to enrolment. 10. Subjects with current, recent or historical donor-specific antibodies. 11. Previous treatment with any desensitisation procedure (with or without intravenous immunoglobulin). 12. Subjects with underlying renal disease with a high risk of disease reoccurrence in the transplanted kidney. 13. Concomitant clinically active local or systemic infection. 14. Use of any experimental medicinal product within 3 months or 5 half-lives prior to the screening visit, whichever is longer, and agreement to not take any experimental medicinal product throughout the trial. 15. Subjects who are currently receiving systemic immunosuppressive agents (e.g., methotrexate, infliximab, adalimumab, corticosteroids) for other indications such as autoimmune diseases, or subjects with comorbidities for which treatment with such agents are likely during the study, with the following exception: • Subjects who are receiving or may require short-term and/or low dose (e.g., prednisone or prednisone equivalent < 5 mg daily) courses of corticosteroids are not precluded from enrolment, at the discretion of the investigator in consultation with the Sponsor’s Medical Monitor. 16. Clinical evidence of significant unstable or poorly controlled acute or chronic diseases (e.g., cardiovascular, pulmonary, haematologic, gastrointestinal, hepatic, neurological, or infectious diseases) or laboratory abnormality (except ESRD) which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk. • Subjects who, at the discretion of the investigator, are deemed at high risk of a renal thrombotic event. 17. Subjects with current or previous history of clinically relevant central nervous system pathology (including but not limited to seizures, stroke, severe brain injury, cerebellar disease or CNS vasculitis). 18. Current or previous history within the last 5 years of malignancy, with the following exceptions: • Subjects with any previous history of haematological malignancy are precluded from enrolment. • Subjects who have had non-melanoma skin cancer or cervical carcinoma in situ that have been successfully treated with no evidence of recurrence are not precluded from enrolment. 19. Subjects whose life expectancy is severely limited by disease state other than renal disease. 20. Subjects with a history of substance abuse (drug or alcohol) within the past 2 years or that is considered not compatible with adequate study follow-up, or psychiatric disorder or other condition that is not compatible with adequate study follow-up. 21. Subjects with laboratory values that meet the following criteria are to be excluded (retesting once during the screening period is permitted at the investigator’s discretion): • Haemoglobin < 10 g/L • Platelets < 80 x 109/L • White blood cells (WBC) < 3 x 109/L • Aspartate transaminase (AST) and or alanine transaminase (ALT) ≥ 3 x upper limit of normal (ULN) • Total bilirubin ≥ 2 x ULN (except for subjects with Gilbert’s disease) 22. Subjects who have received a live attenuated vaccine (LAV) within 30 days prior to their transplantation surgery. 23. Subjects who are currently pregnant, planning pregnancy or breast feeding/lactating while enrolled in the study. 24. Any other reason that, in the opinion of the Site Investigator or Medical Monitor, would render the subject unsuitable for participation in the study.
Exclusion Criteria (All Transplant Donors) 1. Exposure to investigational agents at the time of kidney donation or within 28 days or 5 half-lives whichever is longer, prior to the donation. 2. Any form of substance abuse considered not compatible with adequate study follow-up, psychiatric disorder or other condition that in the opinion of investigator may compromise study participation. 3. Any other reason that, in the opinion of the Site Investigator or Medical Monitor, would render the subject unsuitable for participation in the study. 4. Evidence of active or occult HBV or active HCV infection. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Incidence and grade of TEAEs, including serious adverse events (SAEs) throughout 28 days post TX200-TR101 infusion. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The timepoint of evaluation of the primary endpoint is given in the section above ( E.5.1) |
|
E.5.2 | Secondary end point(s) |
From the day of TX200-TR101 infusion through to Week 84 unless otherwise specified below: •Incidence of BCAR according to the Banff criteria. •Time to first BCAR episode. •Type and severity of any BCAR episodes according to the Banff criteria. •Incidence and grade of TEAEs, including SAEs. •Incidence of opportunistic infections, specifically BK virus (BKV), Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation •Incidence of neoplasia. •Proportion of subjects who are receiving tacrolimus monotherapy at Week 84. •Cumulative dose of immunosuppression, including but not limited to mycophenolic acid (MPA)/mycophenolate mofetil (MMF) and tacrolimus through to Week 84. •Presence of CD4 RNA transcript positive cells that are also positive for HLA-A2 CAR RNA transcripts in the renal transplant biopsy at Week 16. •Incidence and severity of chronic graft dysfunction, as measured by estimated glomerular filtration rate (eGFR). •Incidence and severity of chronic graft dysfunction, as measured by the Banff criteria for chronic rejection including the Banff lesion score inflammation in area of interstitial fibrosis and tubular atrophy (i-IFTA). •Incidence of graft loss due to rejection. •Incidence and (semi-quantitative) intensity of de novo DSA. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The timepoint of evaluation of each secondary endpoint is given in the section above (E.5.2). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
France |
Germany |
Netherlands |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS (Last visit of the last subject) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |